Wiedemann B - Search Results

1

The incidence and development of resistance in Staphylococcus aureus from three European countries.

Wiedemann B, Kresken M. Wiedemann B, et al. J Antimicrob Chemother. 1984 Dec;14 Suppl D:27-34. doi: 10.1093/jac/14.suppl_d.27. J Antimicrob Chemother. 1984. PMID: 6520065

2

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.

Kresken M, Wiedemann B. Kresken M, et al. Among authors: wiedemann b. Antimicrob Agents Chemother. 1988 Aug;32(8):1285-8. doi: 10.1128/AAC.32.8.1285. Antimicrob Agents Chemother. 1988. PMID: 3142353 Free PMC article.

3

Development of resistance in the past decade in central Europe.

Kresken M, Wiedemann B. Kresken M, et al. Among authors: wiedemann b. J Antimicrob Chemother. 1986 Oct;18 Suppl C:235-42. doi: 10.1093/jac/18.supplement_c.235. J Antimicrob Chemother. 1986. PMID: 3804895

4

The epidemiology of beta-lactamases.

Wiedemann B, Kliebe C, Kresken M. Wiedemann B, et al. J Antimicrob Chemother. 1989 Nov;24 Suppl B:1-22. doi: 10.1093/jac/24.suppl_b.1. J Antimicrob Chemother. 1989. PMID: 2691474 Review.

5

[Resistance pattern of clinical bacterial isolates. Results of a super-regional multicenter study of the Resistance Study Committee of the Paul Ehrlich Society of Chemotherapy].

Kresken M, Wiedemann B. Kresken M, et al. Among authors: wiedemann b. Infection. 1987;15 Suppl 4:S150-7. doi: 10.1007/BF01645862. Infection. 1987. PMID: 3312027 Clinical Trial. German.

6

Prevalence of resistance of aerobic gram-negative bacilli to broad-spectrum antibacterial agents: results of a multicentre study.

Kresken M, Jansen A, Wiedemann B. Kresken M, et al. Among authors: wiedemann b. J Antimicrob Chemother. 1990 Jun;25(6):1022-4. doi: 10.1093/jac/25.6.1022. J Antimicrob Chemother. 1990. PMID: 2115035 Clinical Trial. No abstract available.

7

High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.

Kresken M, Henrichfreise B, Bagel S, Brauers J, Wiedemann B. Kresken M, et al. Among authors: wiedemann b. Antimicrob Agents Chemother. 2004 Aug;48(8):3193-5. doi: 10.1128/AAC.48.8.3193-3195.2004. Antimicrob Agents Chemother. 2004. PMID: 15273149 Free PMC article.

8

Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.

Hofbauer H, Naber KG, Kinzig-Schippers M, Sörgel F, Rustige-Wiedemann C, Wiedemann B, Reiz A, Kresken M. Hofbauer H, et al. Among authors: wiedemann b. Infection. 1997 Mar-Apr;25(2):121-6. doi: 10.1007/BF02113592. Infection. 1997. PMID: 9108190 Clinical Trial.

9

[Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy].

Vogel F, Scholz H, al-Nawas B, Elies W, Kresken M, Lode H, Müller O, Naber KG, Petersen E, Shah P, Sörgel F, Stille W, Tauchnitz C, Trautmann M, Ullmann U, Wacha H, Wiedemann B; Paul Ehrlich Society for Chemotherapy. Vogel F, et al. Among authors: wiedemann b. Med Monatsschr Pharm. 2002 Jun;25(6):193-204. Med Monatsschr Pharm. 2002. PMID: 12109028 German. No abstract available.

10

Application of in-vitro models: development of resistance.

Seeberg AH, Wiedemann B. Seeberg AH, et al. Among authors: wiedemann b. J Antimicrob Chemother. 1985 Jan;15 Suppl A:241-9. doi: 10.1093/jac/15.suppl_a.241. J Antimicrob Chemother. 1985. PMID: 3884569

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

302 results

Search Page